

# Ahsun Riaz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3134911/publications.pdf>

Version: 2024-02-01

116  
papers

7,224  
citations

81743

39  
h-index

56606

83  
g-index

119  
all docs

119  
docs citations

119  
times ranked

4410  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. <i>Gastroenterology</i> , 2010, 138, 52-64.	0.6	925
2	Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 497-507.e2.	0.6	566
3	Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 1121-1130.	0.2	305
4	Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. <i>Hepatology</i> , 2009, 49, 1185-1193.	3.6	229
5	Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1358-1365.e1.	2.4	220
6	Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. <i>Journal of Hepatology</i> , 2013, 59, 1029-1036.	1.8	215
7	Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. <i>Hepatology</i> , 2021, 74, 2342-2352.	3.6	215
8	Radiation Lobectomy: Preliminary Findings of Hepatic Volumetric Response to Lobar Yttrium-90 Radioembolization. <i>Annals of Surgical Oncology</i> , 2009, 16, 1587-1596.	0.7	207
9	Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival. <i>Journal of Clinical Oncology</i> , 2009, 27, 5734-5742.	0.8	199
10	Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 163-171.	0.4	199
11	Research Reporting Standards for Radioembolization of Hepatic Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 265-278.	0.2	185
12	Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. <i>Hepatology</i> , 2018, 68, 1429-1440.	3.6	174
13	Improving Inferior Vena Cava Filter Retrieval Rates: Impact of a Dedicated Inferior Vena Cava Filter Clinic. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1847-1851.	0.2	172
14	Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1062.	3.8	170
15	Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. <i>Radiology</i> , 2018, 287, 1050-1058.	3.6	168
16	Incidence of Radiation Pneumonitis After Hepatic Intra-Arterial Radiotherapy With Yttrium-90 Microspheres Assuming Uniform Lung Distribution. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 431-438.	0.6	157
17	Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival Times. <i>Gastroenterology</i> , 2011, 141, 526-535.e2.	0.6	148
18	Chemoembolization for Hepatocellular Carcinoma: Comprehensive Imaging and Survival Analysis in a 172-Patient Cohort. <i>Radiology</i> , 2010, 255, 955-965.	3.6	141

#	ARTICLE	IF	CITATIONS
19	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologicâ€“pathologic correlation. <i>Journal of Hepatology</i> , 2011, 54, 695-704.	1.8	140
20	Radioembolization for Neuroendocrine Liver Metastases: Safety, Imaging, and Long-Term Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 887-894.	0.4	137
21	Side Effects of Yttrium-90 Radioembolization. <i>Frontiers in Oncology</i> , 2014, 4, 198.	1.3	134
22	Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. <i>Journal of Hepatology</i> , 2013, 58, 73-80.	1.8	110
23	Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1-15.	0.2	107
24	Pretransplantation Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Final Analysis of a 61-Patient Cohort. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1714-1721.e2.	0.2	101
25	Radiologic findings following Y90 radioembolization for primary liver malignancies. <i>Abdominal Imaging</i> , 2009, 34, 566-581.	2.0	88
26	Radiologicâ€“Pathologic Correlation of Hepatocellular Carcinoma Treated with Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2010, 33, 1143-1152.	0.9	82
27	Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. <i>Journal of Hepatology</i> , 2012, 56, 1112-1120.	1.8	82
28	Radioembolization for Primary and Metastatic Liver Cancer. <i>Seminars in Radiation Oncology</i> , 2011, 21, 294-302.	1.0	78
29	Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 580-583.	3.3	78
30	Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1502-1510.e1.	0.2	65
31	Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: Analyzing patterns of progression in 285 patients. <i>Hepatology</i> , 2012, 55, 1432-1442.	3.6	64
32	Liver Transplantation Following Yttriumâ€“90 Radioembolization: 15â€“Year Experience in 207â€“Patient Cohort. <i>Hepatology</i> , 2021, 73, 998-1010.	3.6	62
33	Chemoembolization Endpoints: Effect on Survival Among Patients With Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2011, 196, 919-928.	1.0	61
34	Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). <i>Cancers</i> , 2019, 11, 1085.	1.7	60
35	Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1520-1526.	0.2	57
36	<sup>90</sup> Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1042-1048.	2.8	54

#	ARTICLE	IF	CITATIONS
37	Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study. <i>Urology</i> , 2018, 120, 205-210.	0.5	43
38	Prognostic Role of Albumin, Bilirubin, and ALBI Scores: Analysis of 1000 Patients with Hepatocellular Carcinoma Undergoing Radioembolization. <i>Cancers</i> , 2019, 11, 879.	1.7	43
39	Yttrium-90 Radioembolization for Liver Malignancies: Prognostic Factors Associated with Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 90-95.	0.2	42
40	Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses. <i>Hepatology</i> , 2018, 67, 873-883.	3.6	41
41	Chemoembolization and Radioembolization for Metastatic Disease to the Liver: Available Data and Future Studies. <i>Current Treatment Options in Oncology</i> , 2012, 13, 403-415.	1.3	38
42	ASGE guideline on the role of endoscopy in the management of malignant hilar obstruction. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 222-234.e22.	0.5	36
43	Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1487-1494.	0.2	33
44	Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. <i>Radiographics</i> , 2021, 41, 1802-1818.	1.4	33
45	Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation. <i>Journal of Hepatology</i> , 2020, 72, 1151-1158.	1.8	32
46	TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard Care Therapy. <i>Hepatology</i> , 2021, 74, 2735-2744.	3.6	32
47	Optimization of Radioembolic Effect with Extended-shelf-life Yttrium-90 Microspheres: Results from a Pilot Study. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 1557-1563.	0.2	31
48	Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. <i>European Journal of Radiology</i> , 2017, 93, 100-106.	1.2	30
49	Neoadjuvant Radiation Lobectomy As an Alternative to Portal Vein Embolization in Hepatocellular Carcinoma. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 197-203.	2.5	28
50	Yttrium 90 Microspheres for the Treatment of Hepatocellular Carcinoma. <i>Recent Results in Cancer Research</i> , 2013, 190, 207-224.	1.8	28
51	ASGE guideline on the management of cholangitis. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 207-221.e14.	0.5	26
52	Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2018, 43, 1723-1738.	1.0	25
53	Comparing Real World, Personalized, Multidisciplinary Tumor Board Recommendations with BCLC Algorithm: 321-Patient Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1070-1080.	0.9	25
54	Percutaneous Ultrasound-Guided Superior and Inferior Mesenteric Vein Access for Portal Vein Recanalization Transjugular Intrahepatic Portosystemic Shunt: A Case Series. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 496-499.	0.9	23

#	ARTICLE	IF	CITATIONS
55	Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 486-493.	3.3	21
56	Abernethy Malformations: Evaluation and Management of Congenital Portosystemic Shunts. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 788-794.	0.2	21
57	Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1557-1565.	0.9	20
58	Adverse Events Related to Partial Splenic Embolization for the Treatment of Hypersplenism: A Systematic Review. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1118-1131.e6.	0.2	20
59	Yttrium-90 Radioembolization in the Management of Liver Malignancies. <i>Seminars in Oncology</i> , 2010, 37, 94-101.	0.8	18
60	Intra-procedural Transcatheter Intra-arterial Perfusion MRI as a Predictor of Tumor Response to Chemoembolization for Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2011, 18, 828-836.	1.3	17
61	Perfusion Reduction at Transcatheter Intraarterial Perfusion MR Imaging: A Promising Intra-procedural Biomarker to Predict Transplant-Free Survival during Chemoembolization of Hepatocellular Carcinoma. <i>Radiology</i> , 2014, 272, 587-597.	3.6	17
62	Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2195-2202.	3.3	17
63	Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 260-269.	0.9	17
64	Percutaneous management of malignant biliary disease. <i>Journal of Surgical Oncology</i> , 2019, 120, 45-56.	0.8	17
65	Modified Radiation Lobectomy: An Evolving Paradigm to Convert Patients to Liver Resection Candidacy. <i>Seminars in Interventional Radiology</i> , 2019, 36, 343-348.	0.3	17
66	Interventional radiology in the management of the liver transplant patient. <i>Liver Transplantation</i> , 2017, 23, 1328-1341.	1.3	15
67	Contemporary Systematic Review of Health-Related Quality of Life Outcomes in Locoregional Therapies for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1924-1933.e2.	0.2	15
68	Safety of Yttrium-90 Microsphere Radioembolization in Patients with Biliary Obstruction. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1213-1218.	0.2	14
69	Surveillance, anticoagulation, or filter in calf vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 25-32.	0.9	14
70	Technical Aspects and Practical Approach Toward Same-Day Y90 Radioembolization in the Management of Hepatocellular Carcinoma. <i>Techniques in Vascular and Interventional Radiology</i> , 2019, 22, 93-99.	0.4	13
71	MR imaging findings of the prostate gland following prostate artery embolization: results from a prospective phase 2 study. <i>Abdominal Radiology</i> , 2019, 44, 713-722.	1.0	13
72	Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 807-815.	3.3	12

#	ARTICLE	IF	CITATIONS
73	Making the Case: Intra-arterial Therapy for Less Common Metastases. <i>Seminars in Interventional Radiology</i> , 2017, 34, 132-139.	0.3	12
74	New Developments in Interventional Oncology. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 373-380.	1.0	11
75	Percutaneous Access of the Modified Hutson Loop for Retrograde Cholangiography, Endoscopy, and Biliary Interventions. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 2113-2120.e1.	0.2	11
76	Cystitis Cystica and Cystitis Glandularis Causing Ureteral Obstruction. <i>Journal of Urology</i> , 2012, 187, 1059-1060.	0.2	10
77	Indicators of Lung Shunt Fraction Determined by Technetium-99m Macroaggregated Albumin in Patients with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1213-1222.	0.9	10
78	Pretransplant Intra-arterial Liver-Directed Therapy Does Not Increase the Risk of Hepatic Arterial Complications in Liver Transplantation: A Single-Center 10-Year Experience. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 231-238.	0.9	10
79	Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1117-1128.	0.9	10
80	Covered stent use after subclavian artery and vein injuries in the setting of vascular Ehlers-Danlos. <i>Journal of Vascular Surgery</i> , 2012, 55, 542-544.	0.6	9
81	Radioembolization in Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1898-1901.	0.8	8
82	Intrahepatic Cholangiocarcinoma. <i>Seminars in Interventional Radiology</i> , 2020, 37, 475-483.	0.3	8
83	Direct Hepatic Artery Puncture for Transarterial Therapy in Liver Cancer. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 394-399.	0.2	7
84	Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 401-408.e1.	0.2	6
85	Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 211-219.	0.2	6
86	Complications of Percutaneous Biliary Procedures. <i>Seminars in Interventional Radiology</i> , 2021, 38, 364-372.	0.3	6
87	Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 700-711.	0.9	5
88	Gallbladder: Role of Interventional Radiology. <i>Seminars in Interventional Radiology</i> , 2021, 38, 330-339.	0.3	5
89	Post-embolization outcomes of splenic artery pseudoaneurysms: A single-center experience. <i>Clinical Imaging</i> , 2021, 80, 160-166.	0.8	5
90	Percutaneous Biliary Neo-anastomosis or Neo-duct Creation Using Radiofrequency Wires. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 337-343.	0.9	5

#	ARTICLE	IF	CITATIONS
91	Preoperative portal vein recanalizationâ€“transjugular intrahepatic portosystemic shunt for chronic obliterative portal vein thrombosis: Outcomes following liver transplantation. <i>Hepatology Communications</i> , 2022, 6, 1803-1812.	2.0	5
92	Yttrium-90 radioembolization in the management of liver tumors: expanding the global experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 451-452.	3.3	4
93	Future Directions of Percutaneous Biliary Interventions. <i>Seminars in Interventional Radiology</i> , 2021, 38, 373-376.	0.3	4
94	Percutaneous Management of Biliary Stones. <i>Seminars in Interventional Radiology</i> , 2021, 38, 348-355.	0.3	4
95	Percutaneous Biliary Endoscopy. <i>Seminars in Interventional Radiology</i> , 2021, 38, 340-347.	0.3	3
96	Locoregional Therapies for Primary and Secondary Hepatic Malignancies. <i>Cancer Treatment and Research</i> , 2016, 168, 233-256.	0.2	2
97	Endovascular Management of Acquired Hepatic Arterialâ€“Portal Venous Malformations. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 466-477.	0.9	2
98	Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. <i>Advances in Clinical Radiology</i> , 2020, 2, 113-125.	0.1	2
99	Role of Interventional Radiology in the Management of Acute Cholangitis. <i>Seminars in Interventional Radiology</i> , 2021, 38, 321-329.	0.3	2
100	Biliary Anatomy. <i>Seminars in Interventional Radiology</i> , 2021, 38, 251-254.	0.3	2
101	Extrahepatic Applications of Yttrium-90 Radioembolization. <i>Seminars in Interventional Radiology</i> , 2021, 38, 479-481.	0.3	2
102	Reply to S. Kilickap et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e100-e100.	0.8	1
103	Perceptions of Quality in Interventional Oncology. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 367-372.e1.	0.2	1
104	Image-guided Interventions with Endoscopic Guidance. <i>Advances in Clinical Radiology</i> , 2021, 3, 73-83.	0.1	1
105	Combined cut down and endovascular retrieval of orphaned ventriculoatrial shunt with stenting of chronic superior vena cava occlusion. <i>Pediatric Radiology</i> , 2021, 51, 1531-1534.	1.1	1
106	Commentary on Percutaneous Trans-splenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 703-704.	0.9	1
107	Research Priorities in Percutaneous Image- and Endoscopy-Guided Interventions for Biliary and Gallbladder Diseases: Proceedings from the Society of Interventional Radiology Foundation Multidisciplinary Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 1247-1257.	0.2	1
108	Internal radioembolization for colorectal carcinoma liver metastases. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 93-98.	1.0	0

#	ARTICLE	IF	CITATIONS
109	Radioembolization: Clinical Results Hepatocellular Carcinoma. Medical Radiology, 2012, , 379-383.	0.0	0
110	Radioembolization for liver tumors. , 2012, , 1362-1369.e2.		0
111	Embolic Therapies. , 2013, , 101-113.		0
112	Laboratory and Imaging Prognostic Indicators following Arterial Locoregional Therapies for Hepatocellular Carcinoma Survival. Journal of Vascular and Interventional Radiology, 2019, 30, 1893-1894.	0.2	0
113	Does significantly elevated lung shunt fraction (LSF >20%) promote extrahepatic progression in patients with hepatocellular carcinoma treated with radioembolization?. Nuclear Medicine Communications, 2021, 42, 725-731.	0.5	0
114	<i>COL3A1</i> Missense Variant in a Patient Presenting With Hemoptysis. Circulation Genomic and Precision Medicine, 2021, 14, e003386.	1.6	0
115	Trans-cervical thoracic duct embolization for post-surgical left Chylothorax in a patient with multifocal lymphatic malformations. CVIR Endovascular, 2021, 4, 73.	0.4	0
116	Chemoembolization and Radioembolization in the Treatment of Primary Liver Cancers. , 2013, , 327-338.		0